We are live on ! Find out more
NVS icon

Novartis

1,010 hedge funds and large institutions have $20.6B invested in Novartis in 2018 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 371 increasing their positions, 378 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $86M | Put options by funds: $45.7M

64% more capital inflows, than outflows

Capital inflows: $899M | Capital outflows: $550M

18% more first-time investments, than exits

New positions opened: 72 | Existing positions closed: 61

0% more funds holding

Funds holding: 1,005 → 1,010 (+5)

0.2% more ownership

Funds ownership: 12.53% → 12.73% (+0.2%)

0% more funds holding in top 10

Funds holding in top 10: 24 → 24 (0)

2% less repeat investments, than reductions

Existing positions increased: 371 | Existing positions reduced: 378

Holders
1,010
Holders Change
+5
Holders Change %
+0.5%
% of All Funds
23.08%
Holding in Top 10
24
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.55%
New
72
Increased
371
Reduced
378
Closed
61
Calls
$86​M
Puts
$45.7​M
Net Calls
+$40.3​M
Net Calls Change
+$19.1​M

NVS Hedge Fund Activity: Q1 2018 in Review

1,010 of the 4,376 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q1 2018, worth a combined $20.6B — down 2.3% from $21.1B a quarter earlier.

Buyers outnumbered sellers: 72 funds opened new NVS positions and 61 closed out — a net gain of 11 holders — while 371 added to existing stakes and 378 trimmed.

The largest buyer was Loomis, Sayles & Company, adding an estimated $75.4M. The largest seller was Capital Research Global Investors, cutting an estimated $60.2M.

  • 1,010 institutional investors held Novartis (NVS) as of Q1 2018, up from 1,005 in Q4 2017.
  • Funds reported $20.6B of Novartis stock for Q1 2018, down 2.3% quarter-over-quarter.
  • 72 funds opened new Novartis positions in Q1 2018 and 61 closed out, a net change of +11 holders.
  • The largest Novartis buyer in Q1 2018 was Loomis, Sayles & Company, an estimated $75.4M added.
  • The largest Novartis seller in Q1 2018 was Capital Research Global Investors, an estimated $60.2M sold.

Based on aggregated 13F filings for Q1 2018.